Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II
Country flagItaly
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (58)

Purpose: This analysis evaluated the influence of tissue and liquid biopsy concordance on outcomes in patients enrolled in the ROME trial. Patients and Methods: The ROME trial, a phase II multicenter study, enrolled 1,794 patients with advanced solid tumors. Next-generation sequencing was performed on tissue and liquid biopsies using FoundationOne CDx and FoundationOne Liquid CDx. A centralized molecular tumor board reviewed results to identify actionable alterations, with 400 patients randomly assigned to tailored therapy (TT) or standard-of-care groups. TT improved objective response rate and progression-free survival (PFS) in the intention-to-treat population. Concordance was defined as the detection of the same druggable alteration in both biopsy types; discordance indicated detection in only one. Results: Concordance was present in 49% of cases, with alterations detected exclusively in tissue (35%) or liquid (16%) biopsies. Patients in the concordant group receiving TT experienced improved survival outcomes. The median overall survival was 11.05 versus 7.70 months in the standard-of-care group [HR = 0.74; 95% confidence interval, 0.51–1.07], and the median PFS was 4.93 versus 2.80 months (HR = 0.55; 95% confidence interval, 0.40–0.76), respectively. In contrast, the survival benefit of TT was less pronounced or absent in patients with discordant results. Overall survival was higher in the T + L group (11.05 months), followed by tissue-only (9.93 months) and liquid-only (4.05 months) groups. PFS followed a similar pattern, with the longest PFS in the T + L group (4.93 months) versus 3.06 months in tissue-only and 2.07 months in liquid-only groups. Conclusions: The study highlights the potential value of integrating both biopsy modalities in selected clinical contexts. See related commentary by Saldanha and Siu, p. 7

Year:

2026

Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

Year:

2025

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on other antidiabetic drugs/insulin only and those who were not on diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

Kaplan-Meier survival estimates according to the receipt of any diabetes medication. A) Overall Survival NSCLC matched cohort; patients on any diabetes medication: 14.2 months (95%CI: 9.0 – 17.5; 99 events), patients not receiving diabetes medications: 17.5 months (95%CI: 14.2 – 26.6; 77 events). B) Progression Free Survival NSCLC matched cohort; patients on any diabetes medication: 7.9 months (95%CI: 5.4 – 10.8; 113 events), patients not receiving diabetes medications: 10.1 months (95%CI: 7.7 – 13.8; 99 events). C) Overall Survival Melanoma matched cohort; patients on any diabetes medication: 22.9 months (95%CI: 12.0 – NR; 25 events), patients not receiving diabetes medications: NR months (95%CI: 28.8 – NR; 52 events). D) Progression Free Survival Melanoma matched cohort; patients on any diabetes medication: 11.4 months (95%CI: 4.9 – 23.4; 37 events), patients not receiving diabetes medications: 13.8 months (95%CI: 8.7 – 26.0; 77 events). NR: not reached; PSM: propensity score matching.

Year:

2025

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:2, caliper 0.1).

Year:

2025

Summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on metformin only and patients who were not receiving diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

Detailed random blood sugar test results used to compute the median baseline glycaemia (MBG). 133 patients included (30 from the Pascale Cancer Institute and 103 from Imperial College London Cohort.

Year:

2025

Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other diabetes medications/insulin therapy only, and metformin therapy (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving diabetes medications: 18.9 months (95%CI: 15.9-21.6; 684 events), patients on other diabetes medications/insulin therapy only: 19.3 months (95%CI: 11.6-22.9; 48 events), patients on metformin: 12.3 months (95%CI: 9.8-15.9; 100 events). B) Progression Free Survival whole cohort; patients not receiving diabetes medications: 8.2 months (95%CI: 7.1-9.4; 872 events), patients on other diabetes medications/insulin therapy only: 10.7 months (95%CI: 6.7-11.6; 61 events), patients on metformin: 7.9 months (95%CI: 5.1-10.1; 124 events).

Year:

2025

Kaplan-Meier survival estimates according to the number of diabetes medications. A) Overall Survival whole cohort; patients on more than one diabetes medications: 15.5 months (95%CI: 11.1-20.6; 79 events), patients on one medication: 12.5 months (95%CI: 10.0 – 18.9; 69 events), patients not receiving diabetes medications: 18.9 months (95%CI: 15.9 – 21.5; 684 events). B) Progression Free Survival whole cohort; patients on more than one diabetes medications: 7.9 months (95%CI: 6.2-11.4; 101 events), patients on one medication: 8.4 months (95%CI: 4.9 – 11.9; 84 events), patients not receiving diabetes medications: 8.2 months (95%CI: 7.1 – 9.4; 872 events). Polypharmacy: more than one diabetes medication.

Year:

2025

Melanoma cohort - summary of baseline characteristics’ distribution after the propensity score matching procedure between patients on diabetes medications and those who were not receiving diabetes medications (ratio 1:3, caliper 0.1).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (73)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

-

ITALY
View details

Valentina Guarneri

Associate Professor

University of Padova

ITALY
View details

Govind Warrier

Assistant Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

Georgina V. Long

University of Sydney

AUSTRALIA
View details

Maurizio Simmaco

Full Professor Molecular Biology - Director Diparmet Diagnostic sciences

Sapienza University of Rome

ITALY
View details

Leslie A. Fecher

-

UNITED STATES
View details

vanna chiarion sileni

Chief of Melanoma Oncology Unit

-

ITALY
View details

Umberto Malapelle

-

ITALY
View details

Edoardo Crimini

Medical Oncologist

European Institute of Oncology

ITALY
View details

Jessica C. Hassel

Heidelberg University

GERMANY
View details

Massimo Di Nicola

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

James Larkin

Professor

-

UNITED KINGDOM
View details

Giuseppe Tonini

Full Professor of Medical Oncology

Campus Bio Medico University Hospital

ITALY
View details

Marco Gaetano Tucci

Associate Professor

University of Bari

ITALY
View details

Claus Garbe

Professor of Dermatology

Eberhard Karls Universität Tübingen

GERMANY
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Bruno Vincenzi

Professor of Medical Oncology

Università Campus Bio-Medico

ITALY
View details

Reinhard Dummer

University Hospital of Zurich

SWITZERLAND
View details

Ana Arance

University of Barcelona

SPAIN
View details

Nikhil Khushalani

Assistant Center Director for Clinical Research Review and Partnerships; Senior Member and Vice-Chair, Department of Cutaneous Oncology

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Giuseppe Giannini

Head, Unit of Advanced Molecular Diagnostic in Oncology

Sapienza University

ITALY
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Maria Grazia Vitale

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Marcus Butler

University Health Network

CANADA
View details

Lucia Del Mastro

dirigente medico

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro

ITALY
View details

Sebastiano Buti

Ricercatore a contratto tipo B

University of Parma

ITALY
View details

Jean-Jacques Grob

Aix-Marseille University

FRANCE
View details

Wilson H Miller Jr

McGill University

CANADA
View details

Andrea DeCensi

Director

Champalimaud Foundation

PORTUGAL
View details

Lorenzo Nibid

Campus Bio Medico University Hospital

ITALY
View details

Cornelia Mauch

Assistant professor

university hospital of the ruhr university bochum

GERMANY
View details

Giancarlo Pruneri

University of Milan

ITALY
View details

Marco Ferrari

Associate Professor

University of Padova

ITALY
View details

Helen Gogas

Head, Professor in Medical Oncology

National and Kapodistrian University of Athens

GREECE
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Ignacio Melero

Kidani Professor of Cancer Immuno-Therapeutics

University of Oxford

UNITED KINGDOM
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

F. Dimitriou

Attending Physician, Head of Skin Cancer Center

University Hospital of Bern

SWITZERLAND
View details

Maria Giuseppa Vitale

-

ITALY
View details

Giuseppe Curigliano

European Institute of Oncology

ITALY
View details

Lidia Strigari

Head of Department

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Paolo Marchetti

Sapienza University of Rome

ITALY
View details

Paul Nathan

University College London

UNITED KINGDOM
View details

SIMONA PISEGNA

Sapienza University of Rome

ITALY
View details

Alfredo Budillon

Chief Experimental Pharmacology Unit

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY
View details

Francesco Pantano

National Academic Qualification as Full Professor (Abilitazione Scientifica Nazionale a Professore di I Fascia) in Hematology, Oncology and Rheumatology (MED 06/D3)

Ministero dell’Istruzione, dell’Università e della Ricerca

ITALY
View details

Ryan Sullivan

Harvard University

UNITED STATES
View details

Dirk Schadendorf

University Hospital Essen

GERMANY
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Grant McArthur

Lorenzo Galli Chair of Melanoma and Skin Cancers

University of Melbourne

AUSTRALIA
View details

Melissa Bersanelli

Adjunct Professor in Medical Oncology

University of Parma

ITALY
View details

Lucie Heinzerling

University Hospital

GERMANY
View details

Shahneen Sandhu

-

AUSTRALIA
View details

olga nigro

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Alessandro Russo

Humanitas University

ITALY
View details

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Luc Thomas

enseignant-chercheur

Centre de Recherche en Cancérologie de Lyon

FRANCE
View details

Ivan Marquez-Rodas

Universidad Complutense de Madrid

SPAIN
View details

Michele Maio

-

ITALY
View details

Mark Middleton

University of Oxford

UNITED KINGDOM
View details

MICHELE DE TURSI

ASSOCIATE PROFESSOR

University "G. d'Annunzio"

ITALY
View details

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY
View details

Jia Xin Yu

Institute of Cancer Research

UNITED STATES
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details

Mario Mandalà

Associate Professor

University of Perugia

ITALY
View details

Giuseppe Perrone

Università Campus Bio-Medico di Roma

ITALY
View details

Antonio D'Alessio

King's College Hospital

UNITED KINGDOM
View details

Ines Pires da Silva

Medical Oncologist

University of Sydney

AUSTRALIA
View details

Luca Tagliaferri

IRCCS Researcher - Ricercatore IRCCS

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

ITALY
View details